MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CIPLA - SUN PHARMA
CIPLA vs SUN PHARMA - Comparison Results
CIPLA 
Change
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
SUN PHARMA
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Current Valuations
| CIPLA | SUN PHARMA | CIPLA/ SUN PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 32.9 | 28.4 | 116.0% | View Chart |
| P/BV | x | 3.0 | 3.0 | 99.6% | View Chart |
| Dividend Yield | % | 0.6 | 0.4 | 134.7% |
Financials
 CIPLA  SUN PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CIPLA Mar-18 |
SUN PHARMA Mar-18 |
CIPLA/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 663 | 701 | 94.6% | |
| Low | Rs | 479 | 433 | 110.6% | |
| Sales per share (Unadj.) | Rs | 189.0 | 110.4 | 171.2% | |
| Earnings per share (Unadj.) | Rs | 17.6 | 11.0 | 160.3% | |
| Cash flow per share (Unadj.) | Rs | 34.0 | 17.2 | 197.5% | |
| Dividends per share (Unadj.) | Rs | 3.00 | 2.00 | 150.0% | |
| Dividend yield (eoy) | % | 0.5 | 0.4 | 148.9% | |
| Book value per share (Unadj.) | Rs | 176.7 | 158.8 | 111.3% | |
| Shares outstanding (eoy) | m | 805.12 | 2,399.26 | 33.6% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 3.0 | 5.1 | 58.8% | |
| Avg P/E ratio | x | 32.5 | 51.6 | 62.8% | |
| P/CF ratio (eoy) | x | 16.8 | 32.9 | 51.0% | |
| Price / Book Value ratio | x | 3.2 | 3.6 | 90.5% | |
| Dividend payout | % | 17.1 | 18.2 | 93.6% | |
| Avg Mkt Cap | Rs m | 459,724 | 1,360,021 | 33.8% | |
| No. of employees | `000 | 23.6 | 17.8 | 132.7% | |
| Total wages/salary | Rs m | 26,901 | 53,671 | 50.1% | |
| Avg. sales/employee | Rs Th | 6,446.1 | 14,890.9 | 43.3% | |
| Avg. wages/employee | Rs Th | 1,139.4 | 3,017.1 | 37.8% | |
| Avg. net profit/employee | Rs Th | 600.0 | 1,480.6 | 40.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 152,193 | 264,895 | 57.5% | |
| Other income | Rs m | 3,577 | 8,388 | 42.6% | |
| Total revenues | Rs m | 155,769 | 273,282 | 57.0% | |
| Gross profit | Rs m | 28,264 | 56,081 | 50.4% | |
| Depreciation | Rs m | 13,228 | 14,998 | 88.2% | |
| Interest | Rs m | 1,142 | 5,176 | 22.1% | |
| Profit before tax | Rs m | 17,470 | 44,295 | 39.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | -28 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -775 | -9,505 | 8.2% | |
| Tax | Rs m | 2,501 | 8,452 | 29.6% | |
| Profit after tax | Rs m | 14,166 | 26,338 | 53.8% | |
| Gross profit margin | % | 18.6 | 21.2 | 87.7% | |
| Effective tax rate | % | 14.3 | 19.1 | 75.0% | |
| Net profit margin | % | 9.3 | 9.9 | 93.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 108,141 | 316,359 | 34.2% | |
| Current liabilities | Rs m | 38,322 | 198,643 | 19.3% | |
| Net working cap to sales | % | 45.9 | 44.4 | 103.2% | |
| Current ratio | x | 2.8 | 1.6 | 177.2% | |
| Inventory Days | Days | 97 | 95 | 102.3% | |
| Debtors Days | Days | 74 | 108 | 69.1% | |
| Net fixed assets | Rs m | 109,411 | 213,178 | 51.3% | |
| Share capital | Rs m | 1,610 | 2,399 | 67.1% | |
| "Free" reserves | Rs m | 140,682 | 378,606 | 37.2% | |
| Net worth | Rs m | 142,292 | 381,006 | 37.3% | |
| Long term debt | Rs m | 36,621 | 17,721 | 206.7% | |
| Total assets | Rs m | 228,606 | 643,028 | 35.6% | |
| Interest coverage | x | 16.3 | 9.6 | 170.5% | |
| Debt to equity ratio | x | 0.3 | 0 | 553.3% | |
| Sales to assets ratio | x | 0.7 | 0.4 | 161.6% | |
| Return on assets | % | 6.7 | 4.9 | 136.6% | |
| Return on equity | % | 10.0 | 6.9 | 144.0% | |
| Return on capital | % | 10.0 | 10.0 | 99.3% | |
| Exports to sales | % | 32.8 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | 49,883 | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 51,691 | 40,816 | 126.6% | |
| Fx outflow | Rs m | 21,033 | 30,143 | 69.8% | |
| Net fx | Rs m | 30,658 | 10,673 | 287.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 14,628 | 39,072 | 37.4% | |
| From Investments | Rs m | -8,540 | -33,708 | 25.3% | |
| From Financial Activity | Rs m | -3,855 | -15,393 | 25.0% | |
| Net Cashflow | Rs m | 2,431 | -7,359 | -33.0% | |
Share Holding
| Indian Promoters | % | 16.0 | 63.7 | 25.1% | |
| Foreign collaborators | % | 20.8 | 0.0 | - | |
| Indian inst/Mut Fund | % | 12.2 | 5.1 | 237.8% | |
| FIIs | % | 23.7 | 23.0 | 103.0% | |
| ADR/GDR | % | 1.1 | 0.0 | - | |
| Free float | % | 26.2 | 8.3 | 315.7% | |
| Shareholders | 161,166 | 133,026 | 121.2% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.5 | - |
Compare CIPLA With: FRESENIUS KABI ONCO. DIVIS LABORATORIES FULFORD INDIA ALEMBIC PHARMA ELDER PHARMA
Compare CIPLA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Get Ready for Record Highs(Podcast)
Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.
Related Views on News
CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.
SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)
Nov 14, 2018 | Updated on Nov 14, 2018For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)
Nov 12, 2018 | Updated on Nov 12, 2018For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsMost Popular
My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)
Mar 19, 2019The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.
5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)
Mar 15, 20195 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.
This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)
Mar 19, 2019If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.
Elections Don't Matter!(The Honest Truth)
Mar 13, 2019Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.
Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)
Mar 13, 2019The elements that fueled profit growth for these two companies led to a surge in their stock prices.
More|
| |
CIPLA SHARE PRICE
Mar 22, 2019 (Close)
TRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA 8-QTR ANALYSIS
COMPARE CIPLA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.